Nitric oxide is a ubiquitous free radical that plays a key role in a broad spectrum of signaling pathways in physiological and pathophysiological processes. We have explored the transcriptional regulation of inducible nitric oxide synthase (iNOS) by the Kruppellike factor 6 (KLF6), an Sp-1 like zinc finger transcription factor. Study of serial truncation constructs of the iNOS promoter revealed that the proximal 0.63 kb region can support a 3 to 6 fold reporter activity similar to that of the full length 16 kb promoter.
INTRODUCTION
Nitric oxide synthases (NOS) are key proteins that produce nitric oxide (NO) and thereby regulate many important biological processes. NO is generated during the oxidation of L-arginine to L-citrulline by at least three different isoforms of NOS.
Endothelial and neuronal NOS are constitutively expressed and their activity is Ca 2+ and calmodulin dependent, whereas the third isoform is transcriptionally inducible (iNOS) and its activity is independent of Ca 2+ and calmodulin, and can produce very high levels of nitric oxide over a sustained period of time (1;2) . It has been shown that iNOS is transcriptionally upregulated in pathophysiologic conditions such as hypoxia, ischemiareperfusion injury, trauma and by reactive oxygen species (ROS) (3;4) .
NO is a key central molecule in cellular biochemical processes as it is freely diffusible and traverses cell membranes to reach different targets, alters signaling networks by redox-sensitive modifications and transcriptionally regulates multiple gene families (5) (6) (7) (8) (9) (10) . NO production following iNOS up-regulation is associated with increased wound healing and repair in tissue injury (11;12) . NO is also known to activate multiple gene and cell signaling pathways through processes such as nitrosation and cGMP production (3;9). Furthermore, numerous studies have shown that NO has antitumor effects and forced expression of iNOS causes regression of tumors (13) (14) (15) (16) .
Kruppel-like factor (KLF6) is a ubiquitously expressed member of the Kruppel like family of transcription factors that have characteristic Cys2/His2 zinc finger motifs and bind very similar "GC-box" or "CACCC element" sites on DNA (17;18) . KLF6 is an immediate early gene that regulates the expression of multiple genes and is involved in tissue differentiation (19) (20) (21) (22) (23) . KLF6 is rapidly induced in cells after acute injury and directly activates collagen α 1 and TGFβ along with TGFβ receptor I and II genes thereby mediating wound healing mechanisms of fibrogenesis and extracellular matrix formation (18;24) . Recently, KLF6 has been shown to function as a tumor suppressor gene that was mutated in prostate cancer (25) .
The iNOS promoter defines a number of NF-κB and AP-1 sites dispersed through out the 16 kb region. A number of iNOS inducers including cell injury, heat shock and various cytokines have been found to exert their effect by activating either NF-κB or AP-1 (1;26-28) . Since KLF6 and iNOS are involved in common processes such as cell injury and wound repair, embryogenesis, tissue differentiation and suppression of tumorigenesis and because the iNOS promoter defines multiple CACCC sites (KLF6 binding motifs), we hypothesized that KLF6 binds to the iNOS gene and regulates its expression.
In the present study we have identified a novel transcriptional regulator of iNOS.
Specifically, we demonstrate that KLF6 binds to CACCC sites within the proximal 0.63 kb and regulates the expression of the iNOS promoter in various cell types. We also show that in cells, exposed to stress conditions, the enhanced expression of KLF6 causes a direct increase in expression of the endogenous iNOS gene and NO.
MATERIALS AND METHODS

Cell Culture
Jurkat cells were cultured in RPMI medium (Life Technologies, Carlsbad, CA) supplemented with 10 % FBS. Cos-7 cells were maintained in DMEM (Life technologies) supplemented with 10 % FBS. Peripheral blood mononuclear cells (PBMCs) were obtained from healthy adult volunteers. Primary T lymphocytes were obtained from PBMCs using a pan T-cell isolation kit according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). The protocol of study was approved by the Health Use Committee of the Walter Reed Army Institute of Research, Silver Spring,
MD.
Plasmid Constructs
The human iNOS luciferase reporter constructs 0.63, 1.3, 3.8, 5.8, 7.2 and 16.0 kb upstream have been previously described (29) . The two CACCC sites in the 0.63 kb iNOS promoter were mutated to AAAAA using the Quikchange™ XL site directed mutagenesis kit (Stratagene, La Jolla, CA). The mutations were confirmed by sequencing. The promoterless luciferase gene vectors pXP1 and pXP2 were used as control vectors. The Thymidine kinase-iNOS promoter luciferase constructs have been described previously (29) . The KLF6 expression vector, pXCPBP and the control vector pX (pBluescript) have been described previously (30) . The p50 and p65 NF-κB vectors were a kind gift from Dr. Barbara Rellahan (Center for Biologics Evaluation and Research, FDA, Bethesda MD)
Transient Transfections and Luciferase Activity Assays
Plasmid DNA transfections of Jurkat T cells and Cos-7 cells were carried out in 24 well plates (Corning Inc., Corning, NY) using LipofectAMINE TM 2000 Reagent (Life Technologies) as per the manufacturer's protocol. The day before transfection, 6 x 10 4 Cos-7 cells or 0.6 x 10 6 Jurkat T cells were plated in 0.5 ml medium per well. For each well, lipofectamine reagent (2-3 µl) was mixed with plasmid DNA (1.5 µg) in serum free OPTI-MEM medium to allow DNA-lipofectamine reagent complexes to form. The complexes were added to respective wells and mixed by gently rocking the plate back and forth. The cells were incubated in a CO 2 incubator at 37°C for 48 h and then lysed with 60 µl reporter lysis buffer (Promega, Madison, WI). Luciferase activity was assayed with 20 µl of lysate and 80 µl of luciferase assay reagent (Promega) in a TD20/20 luminometer (Promega). Transfection efficiency was determined in all samples by cotransfection with 0.5 µg of a plasmid encoding the cytomegalovirus promoter driven β-galactosidase gene and the luciferase activity was normalized to the β-galactosidase activity.
Electrophoretic Mobility Shift Assay (EMSA)
Cos-7 cells (2 x 10 6 ) were transfected with the KLF6 expression vector overnight. Briefly, the transfected cells were detached using trypsin-EDTA, washed with phosphate buffered saline and nuclear extracts were prepared as described 
Chromatin Hybridization Immunoprecipitation Assay (ChIP)
Cos-7 cells (10 x 10 6 ) were transfected with KLF6 expression vector or were non-transfected (control). Both, the transfected and control cells were divided into two subgroups, one was untreated and the other treated with 20 mM sodium cyanide (NaCN) for 3 h and both subgroups were used for the ChIP assay. Jurkat and T lymphocytes (10 x 10 6 ) were also treated similar to Cos-7 cells, however only the Cos-7 cells were subject to KLF6 transfection. Moreover all the cells were also treated with PMA/A23187 or heat shock or serum starved and subjected to ChIP analysis. The ChIP assay was performed as per the manufacturer's recommendation (Upstate Biotechnology, Lake Placid, NY) and previously published protocols (32) (33) (34) . Briefly, KLF6 was cross-linked to DNA by adding formaldehyde to a final concentration of 1%. The chromatin samples for studying phosphorylated KLF6 were incubated with anti-phosphoserine (clone PSR-45) (Sigma) and anti-phosphotyrosine (clone 4G10) antibodies (Santa Cruz Biotechnology) overnight at 4°C and immunoprecipitated with salmon sperm DNA-BSA-Sepharose beads, followed by treatment with 10 mM phenylphosphate for 15 min. The supernatants were used for further steps. All the samples (for phosphorylated as well as nonphosphorylated KLF6) were then incubated overnight at 4°C with anti-KLF6 antibody (Santa Cruz Biotechnology) followed by incubation with Sepharose beads. The immunocomplexes were treated with DNAse and RNAse free proteinase K, and DNA was purified by a DNA purification kit (Qiagen, Santa Clara, CA). PCR was performed with primers flanking the proximal as well as distal KLF6 binding sites in the proximal 0.63 kb iNOS promoter (52 CAG AGA GCT CCC TGC TGA GGA AA 32 and 52 GAG AGT TGT TTT TGC ATA AAG GTC TC 32) (Fig. 5 ). Amplified fragments (321 bp) were analyzed on a 2 % agarose gel by Syber Green (FMC Bioproducts, Rockland, ME) staining. The no-antibody immunoprecipitation samples served as negative control.
Real-time quantitative PCR
Total RNA was isolated from 5 x 10 6 control cells using RNeasy mini kit 
SDS-PAGE and Immunoblotting
Quantitation and Statistical Analysis
Statistical analysis of the data was done with Minitab, Version 14 using student's t test and p value < 0.05 was considered as significant (Minitab, State College, PA). The Western blot bands were quantitated by GelPro TM software (Media Cybernetics, Silver Spring, MD). Transfection of Cos-7 cells with p65 and p50 with the full-length iNOS promoter construct induced promoter activity by 2 and 4 fold, respectively (Fig. 1B) . These results indicate that KLF6 can induce the transcription of the iNOS promoter at levels comparable to those induced by NF-κB (4;26;29;38;39).
RESULTS
KLF6 induces iNOS promoter activity in Cos-7 cells
The proximal 0.63 kb iNOS promoter is sufficient for the induction of activity by KLF6
After ascertaining that KLF6 can activate the full-length 16 kb iNOS promoter, we performed transfection experiments to define the region of the iNOS promoter that is required for the induction of transcription by KLF6 (29) . Cos-7 and Jurkat cells were transfected with serial deletion constructs of the 16 kb iNOS promoter-luciferase reporter compared to cells transfected with control vector, demonstrated that the induction of iNOS promoter activity remained similar in all constructs compared to the full length 16 kb iNOS promoter ( Fig. 2A and B) . Previous studies have shown that KLF6 binds to the CACCC motifs of DNA (40) . The 0.63 kb iNOS construct has two CACCC motifs and there are a total of ten CACCC binding sites in the first 8 kb of the 16 kb iNOS promoter.
Optimum induction (3 fold) of the 0.63 kb iNOS promoter by KLF6 ( Fig. 2A and B) suggests that additional upstream KLF6 binding sites do not further enhance the iNOS promoter activity in the presence of CACCC sites in the proximal 0.63 kb. However, when the iNOS core promoter with the CACCC sites (within 0.63 kb) was replaced by thymidine kinase (TK-Luc) core promoter, a 20% increase in the luciferase activity with KLF6 expression vector (compared to transfection with control vector Px) was observed with the 3.8-5.8 kb iNOS and 7.2-16 kb iNOS TK-Luc constructs, whereas there was no luciferase induction with the iNOS promoter region from 5.8-7.0 kb (Fig. 2C) . The significance of this finding is presently unknown.
Mutational analysis of the two CACCC sites in the 0.63 kb iNOS promoter
In order to understand the contribution of KLF6 to the activation of the 0.63 kb iNOS promoter by the two CACCC sites, we created single mutation constructs in which we mutated the proximal or distal CACCC sites individually, or a dual mutation construct with both CACCC sites mutated. Transfection studies with these mutants revealed that the two sites that are separated by 92 bases, had an additive effect in the stimulation of the 0.63 kb iNOS promoter. The distal CACCC site contributed to a 1.6-and 3.2-fold induction of luciferase activity in Cos-7 cells (Fig. 3A) and Jurkat cells (Fig. 3B) respectively. Similarly, the proximal CACCC site contributed to a 1.3-and 2-fold induction in Cos-7 cells (Fig. 3A) Jurkat cells (Fig. 3B) , respectively. Mutation of both CACCC sites completely abolished the KLF6-induced iNOS promoter activity suggesting that the CACCC motifs are necessary for the interaction of KLF6 with the 0.63 kb iNOS. These studies demonstrate that the proximal and distal CACCC sites in the 0.63 kb iNOS promoter are necessary for optimal basal promoter activity.
KLF6 binds to the CACCC sites in the 0.63kb iNOS promoter
To demonstrate that KLF6 binds to the human iNOS promoter, we designed two oligonucleotides, each defining the CACCC motif regions at positions -164 to -168 and -261 to -265 in the 0.63 kb iNOS promoter, respectively (41) . The primers were end labeled and an EMSA was performed using nuclear extracts from KLF6 transfected Cos-7 cells. Nuclear extracts from these cells bound to both oligonucleotides defined by the 0.63 kb iNOS promoter (Fig. 4A and B) . To demonstrate the specificity of the binding, super-shift assays were performed using an antibody specific to KLF6. As shown in lane 4 of both Fig. 4A and B, the shifted band in lane 1 was super-shifted by an anti-KLF6 antibody demonstrating that KLF6 directly interacts with the iNOS promoter in vitro. Absence of a super-shifted band with anti-KLF4 antibody (lane 2 of both Fig. 4A and B) further confirmed the specificity of KLF6 for the CACCC binding sites.
In vivo binding of KLF6 to the iNOS promoter
Next, to determine whether KLF6 interacts with iNOS in vivo, we performed ChIP analysis using primary T cells, Jurkat cells and Cos-7 cells. The KLF6-DNA complexes were then immunoprecipitated with anti-KLF6 antibody, followed by reversal of cross-linking and PCR amplification using primers flanking the proximal and distal CACCC binding sites in the 0.63 kb iNOS promoter (Fig. 5A) . In transfected Cos-7 cells, the intensity of the PCR product was significantly higher compared to the nontransfected cells (Fig. 5B) (lane 2 versus lane 4) suggesting that increased expression of KLF6 increases its binding to the iNOS promoter.
It has been demonstrated in independent studies, that iNOS and KLF6 are upregulated in cell stress (3;4;18;24) . In order to examine whether upregulation of iNOS is mediated by KLF6 under conditions of stress, we treated Cos-7 cells, Jurkat cells and primary T lymphocytes with NaCN. NaCN blocks mitochondrial respiration and induces cellular hypoxia (42) . As shown in Fig. 5B (lanes 3, 5, 7 and 9) treatment with NaCN strongly increased the binding of KLF6 to the iNOS promoter as evidenced by the increased intensity of the PCR product.
We also subjected Cos-7, Jurkat and primary T cells to heat stress, serum starvation and PMA/A23187 and analyzed the binding of KLF6 to the iNOS promoter by ChIP. As shown in Fig. 5C , compared to the control cells, the KLF6 binding to iNOS promoter was increased in a similar fashion in all cell types subjected to these conditions. These data conclusively show that the association of KLF6 to the iNOS promoter is increased in cells subjected to conditions of stress and stimulation.
Next we asked if the phosphorylation status of KLF6 could play a role in its binding to the iNOS promoter. To ascertain whether serine and tyrosine phosphorylation of KLF6 plays a role in binding to the iNOS promoter, we performed ChIP analysis involving a two-step immunoprecipitation process using anti-phosphoserine or anti-phosphotyrosine followed by treatment with phenyl phosphate (to separate the phosphorylated protein from the bound antibody) and further immunoprecipitation with anti-KLF6
antibodies. The data shows that the KLF6 that binds to iNOS is serine phosphorylated in resting T cells which increases in PMA/A23187 and NaCN treated cells (Fig. 5D) . Interestingly, however we observed that tyrosine phosphorylated KLF6 binds to the iNOS promoter only in NaCN treated cells. The absence of any PCR products for the no-antibody and mouse IgG immunoprecipitation controls further confirmed the specificity of our findings (data not shown). Thus, differential phosphorylation of KLF6 mediates differential binding to iNOS in various conditions.
Induction of iNOS mRNA, protein and NO in KLF6 transfected cells
To establish the functional association between KLF6 expression and expression of iNOS, we measured the iNOS mRNA, protein and NO production in KLF6 transfected Cos-7 cells. We performed real-time PCR to estimate the fold induction of mRNA, based on the fluorescence cycle threshold (Ct) differences between various time points compared to their controls. As shown in Fig. 6A , the production of KLF6 mRNA was induced up to 14-fold 24 h post-transfection and 13-fold 48 h post-transfection, respectively (Fig. 6A ). In tandem with the KLF6 mRNA there was a corresponding increase in the iNOS mRNA which showed a steady increase ranging from 3.5-fold (24 h) to 6-fold (48 h) (Fig. 6A) . There was no increase in the control (GAPDH) mRNA.
Next, in order to study the kinetics of iNOS protein induction by KLF6 following KLF6 expression vector transfection, we performed Western blot experiments at earlier time points (0-18h) (Fig.   6B ) and pursued the kinetics of KLF6 and iNOS expression over 72 h (Fig. 6C) . KLF6 protein levels increased starting at 6h post-transfection, whereas iNOS protein levels increased starting at 12h posttransfection, suggesting that KLF6 is able to initiate transcription and produce iNOS protein within 6 h (Fig. 6B) . It was previously observed that an increase in KLF6 mRNA in culture activated cells was accompanied by an even greater increase in KLF6 protein (18) , moreover the rate of degradation of KLF6 protein was also lower (18) . In light of these data, we believe that the induction of KLF6 protein seen beyond 48 h could be attributed to accumulation of KLF6 as a result of decreased protein degradation (Fig. 6C) .
Furthermore, NO production, as measured by assay for NO metabolites, nitrite and nitrate, indicated a significant increase in cells transiently transfected with KLF6 (Fig. 6D) . There was no increase in either KLF6 or iNOS mRNA, protein (data not shown) or NO in control vector transfected cells (Fig. 6D ) and cells subjected to lipofectamine transfection agent (data not shown), incubated under similar culture conditions as the KLF6 transfected cells. These data, taken together with the ChIP results (Fig. 5) , demonstrate that KLF6 acts as a transactivator of the iNOS gene.
NaCN-induced hypoxia upregulates KLF6 and iNOS mRNA and protein as well as NO in Cos-7 cells
ChIP analysis (Fig. 5A ) demonstrated increased binding of KLF6 to the iNOS promoter in cells exposed to NaCN. Therefore, to establish a functional association between the expression of KLF6 and iNOS in pathophysiological conditions, we measured the KLF6 and iNOS mRNA, protein and NO production in NaCN treated Cos- there was an increase in the KLF6 protein by 24 h and the high amounts were sustained over a 72 h period. The iNOS protein levels were also induced by 12 h and the levels reached a peak by 48 h. (Fig. 7B) . Furthermore, NO production, as assayed by its metabolites nitrite and nitrate, also indicated a significant increase in the nitrite + nitrate levels, starting at 6 h with a steady and sustained increase over 72 h (Fig. 7C) . Thus, even though we cannot rule out the additional effect of other transcription factors in the induction of iNOS following NaCN treatment, the above data combined with our ChIP findings (Fig. 5B) and increased iNOS mRNA and protein expression data following KLF6 transfection (Fig. 6 A and B) , strongly suggest that KLF6 plays a role in iNOS induction following treatment of cells with NaCN.
DISCUSSION
Our study provides first evidence for the regulation of the human iNOS promoter by a member of the Kruppel-like family of transcription factors. Using luciferase reporter gene assays, EMSA and ChIP, we demonstrate that KLF6, a member of the Kruppel-like family of transcription factors, directly interacts with the iNOS promoter in resting cells, and with greater intensity following cell stress, injury and stimulation. Furthermore, we show that the upregulated KLF6 increases both iNOS mRNA and protein that correlates functionally with concomitant nitric oxide expression.
The presented evidence strongly suggests that KLF6 is a major transcriptional regulator of iNOS in conditions of hypoxia and cell stress.
The human iNOS promoter is 16 kb long and is one of the largest known promoters (1). Its regulation is complex and occurs at multiple levels, orchestrated by multiple transcription factors, in response to diverse conditions in tissue specific context. Multiple transcription factors such as NF-κB, AP1, Stat 1α and interferon regulatory factor are known to regulate the iNOS promoter (reviewed in detail in (1)). NF-κB is ubiquitously expressed and regulates iNOS in multiple cell types and the regulation of iNOS by NF-κB is well characterized (4;26;29;38;39) . Our data demonstrate that the induction of iNOS by KLF6 was comparable to that by the NF-κB subunits, suggesting that KLF6 could be an equally important regulator of iNOS.
Despite the presence of at least ten CACCC sites in the 16 kb iNOS promoter, the KLF6 induced transcriptional activation of the 0.63 kb construct was similar to that of the 16 kb construct in Cos-7 and Jurkat cells (Fig. 2) . The CACCC sites in the 0.63 kb construct are placed in close proximity at -164 and -261 as compared to the other CACCC sites, the nearest of which is much farther upstream at -2736. Previous studies have reported similar binding of KLF6 to either tandem sites or sites in close proximity to each other in other promoters and placed in close proximity to the basal promoter elements. KLF6 is known to bind the leukotriene C4 synthase promoter at two tandem CACCC sites located between -135 and -149 close to the basal promoter elements (40) . In yet another study, KLF6 was shown to interact with TGF-β1and both TGF-β receptor I and II promoters at multiple sites. KLF6 strongly transactivates TGFβ-1 by binding to (49) . In NaCN treated cells, we observed increased binding of KLF6 to the iNOS promoter (Fig. 5B) , in addition to increased levels of iNOS protein and concomitant NO production ( Fig. 7B and C) . In a similar study, it has been shown that NO protected NaCN treated chick embryonic neurons from cyanide-induced apoptosis (42) .
NO plays a role in wound healing and tissue repair. In several studies including colon anastomosis, bone fracture and cutaneous wound healing, the reparative role of NO through upregulation of iNOS has been well demonstrated (10;50;51) . Similarly, KLF6 plays a direct anti-apoptotic role in conditions of acute injury. KLF6 was found to be responsible for healing of acutely injured hepatic stellate cells (18) and aortic endothelial cells (52) . Our ChIP data (Fig. 5B) demonstrate that in heat shock and NaCN treated cells there is a strong binding of KLF6 to the iNOS promoter, thereby suggesting that KLF6 can orchestrate its anti-apoptotic and protective effects by upregulating NO through iNOS (Fig. 6) Recently, KLF6 was demonstrated to be a tumor suppressor gene that was found mutated in 77% of prostate cancer patients, and it was shown to act in a p53 independent manner through the p21 (Waf1/Cip1) pathway (25) . The tumor suppressive role of iNOS is also well documented (13;15;16) . NO production by iNOS through its transcriptional upregulation by KLF6 of could serve as another mechanism for the anti-tumor effect of KLF6.
In conclusion, our findings provide evidence that KLF6 binds to the human iNOS promoter and regulates its expression in conditions of cell stress, injury and stimulation, with possible implications in the treatment of organ injury and cancer. 
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